Glucagon-like peptide-1: Physiology therapeutic potential

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 1, 2005, Pages 56-62

  Holst, Jens Juul ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dipeptidyl peptidase IV; DPP IV; Exendin; Incretin hormones; Type 2 diabetes

Indexed keywords

ALBUGON; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DP 728; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

APPETITE; CARDIOVASCULAR FUNCTION; DIGESTION; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INACTIVATION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; METABOLIC REGULATION; NAUSEA; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PLASMA HALF LIFE; PRURITUS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 14944371913     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000151395.52819.47     Document Type: Review

References (78)

1. Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287:E199-E206. This review provides an overview the current status of incretin function in humans.
2. Furuta M, Yano H, Zhou A, et al. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A 1997; 94:6646-6651.
3. Ugleholdt R, Zhu X, Deacon CF, et al. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 2004; 145:1349-1355.
4. Drucker DJ: Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17:161-171.
5. Holst JJ: Glucagon-like peptide 1 (Glucagon-like peptide-1): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10:229-234.
6. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional statue in short-bowel patients with no colon. Gastroenterology 2001; 120:806-815.
7. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18:2180-2189.
8. Holst JJ: Treatment of type 2 diabetes mellitus with agonists of the Glucagon-like peptide-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004; 9:155-166.
9. Fehmann HC, Goke R, Goke B: Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16:390-410.
10. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2:1300-1304.
11. Kolligs F, Fehmann HC, Goke R, et al. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995; 44:16-19.
12. Wang Z, Wang RM, Owji AA, et al. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 1995; 95:417-421 [see comments].
13. Edwards CM, Todd JF, Mahmoudi M, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48:86-93 [in-process citation].
14. Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2:1254-1258.
15. Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology. XXXV. The Glucagon Receptor Family. Pharmacol Rev 2003; 55:167-194. This is a very comprehensive and useful review of the current knowledge regarding this family of receptors
16. Fehmann HC, Habener JF: Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130:159-166.
17. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42:856-864 [in-process citation].
18. Egan JM, Bulotta A, Hui H, et al. Glucagon-like peptide-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 2003; 19:115-123.
19. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48:2270-2276.
20. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49:741-748.
21. Zhou J, Wang X, Pineyro MA, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48:2358-2366.
22. Perfetti R, Zhou J, Doyle ME, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141:4600-4605.
23. Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004; 47:806-815. This study demonstrates the ability of Glucagon-like peptide-1 to counteract apoptosis in human β cells, whether induced by lipotoxicity, glucotoxicity, or both.
24. Brubaker PL, Drucker DJ: Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145:2653-2659. This is a useful review of the current status with respect to the intracellular mechanisms involved in the protective effects of Glucagon-like peptide-1
25. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86:3717-3723.
26. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated Glucagon-like peptide-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38:665-673.
27. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273:E981-E988.
28. Nauck MA, Niedereichholz U, Ettler R, et al. Inhibition of gastric emptying by physiological and pharmacological doses of exogenous glucagon-like peptide-1 (Glucagon-like peptide-1) outweighs insulinotropic effects in healthy normoglycemic volunteers. Am J Physiol 1997.
29. Layer P, Holst JJ, Grandt D, et al. Ileal release of glucagon-like peptide-1 (Glucagon-like peptide-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40:1074-1082.
30. Schirra J, Nicolaus M, Struckmeier C, et al. Regulation of antro-pyloro-duodenal and proximal gastric motility by Glucagon-like peptide-1: involvement of a cholinergic pathway. Regul Peptide 2004; 122:37. Although still in abstract form, this study is important because it demonstrates for the first time that Glucagon-like peptide-1 is a physiologic regulator of gastric motility.
31. Read N, French S, Cunningham K: The role of the gut in regulation food intake in man. Nutr Rev 1994; 52:1-10.
32. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101:515-520.
33. Gutzwiller JP, Ke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44:81-86.
34. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (Glucagon-like peptide-1) in obese men. Int J Obes Relat Metab Disord 1999; 23:304-311.
35. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276:R1541-R1544.
36. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86:4382-4389.
37. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379:69-72 [see comments].
38. Tang-Christensen M, Larsen PJ, Goke R, et al. Central administration of Glucagon-like peptide-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271:R848-R856,
39. Goke R, Larsen PJ, Mikkelsen JD, et al. Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 1995; 62:130-134.
40. Tang-Christensen M, Vrang N, Larsen PJ: Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998; 47:530-537.
41. Larsen PJ, Tang-Christensen M, Holst JJ, et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem, Neuroscience 1997; 77:257-270.
42. Rinaman L: Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 1999; 277:R582-R590.
43. Rinaman L: A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol 1999; 277:R1537-R1540.
44. Lachey JL, D'Alessio DA, Rinaman L, et al. The role of central Glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 2005; 146:458-462.
45. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137:2968-2978.
46. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144:2242-2252. This study demonstrates that mice without a Glucagon-like peptide-1 receptor have impaired cardiac function, suggesting that endogenous Glucagon-like peptide-1 has a physiologic role in cardiac function.
47. Bose AK, Mocanu MM, Mensah KN, et al. Glucagon-like peptide-1 protects schemic and reperfused myocardium via PI3Kinase and p42/p44 MARK signalling pathways [abstract]. Diabetes 2004; 53(suppl): A1.
48. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109:962-965. This study shows that Glucagon-like peptide-1 treatment may have beneficial effects on cardiac function, which is of great relevance for diabetes patients.
49. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110:955-961. This study shows that Glucagon-like peptide-1 treatment may have beneficial effects on cardiac function, which is of great relevance for diabetes patients.
50. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110:43-52.
51. Yamamoto H, Kishi T, Lee CE, et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003; 23:2939-2946.
52. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359:824-830.
53. Perry T, Haughey NJ, Mattson MP, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302:881-888.
54. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9:1173-1179.
55. Perry TA, Greig NH: A new Alzheimer's disease interventive strategy. Glucagon-like peptide-1. Curr Drug Targets 2004; 5:565-571.
56. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:741-744.
57. Rachman J, Barrow BA, Levy JC, et al. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (Glucagon-like peptide-1) in subjects with NIDDM. Diabetologia 1997; 40:205-211.
58. Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88:220-224.
59. Deacon CF, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271:E458-E464.
60. Ehlers MRW, Roderick EH, Schneider RL, et al. Continuous subcutaneous infusion of recombinant Glucagon-like peptide-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes [abstract]. Diabetes 2002; 51(suppl 2):A579.
61. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and post-prandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281:E155-E161.
62. Buse JB, Henry RR, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628-2635. This is the first published study on the long-term effects of type 2 diabetes with an exendin-based Glucagon-like peptide-1 receptor activator.
63. Hiles R, Carpenter T, Serota D, et al. Exenatide does not cause pancreatic tumours or malignancies in rats and mice following a 2-year period of exposure [abstract]. Diabetes 2004; 53(suppl 2):A380.
64. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative Liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
65. Knudsen LB, Agersø H, Bjenning C, et al. Glucagon-like peptide-1 derivatives as novel compounds for the treatment of type 2 diabetes. Drugs Future 2001; 26:677-685.
66. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog Liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27:1335-1342. This is the first study of the long-term effects of diabetes treatment with an albumin bound Glucagon-like peptide-1 analog.
67. Nauck M, Hompesch M, Filipczak R, et al. Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride [abstract]. Diabetologia 2004; 47(suppl 1):A281.
68. Kim JG, Baggio LL, Bridon DP, et al. Development and characterization of a glucagon-like peptide 1 -albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52:751-759. This study shows how remarkably well Glucagon-like peptide-1 functions even when covalently bound to a molecule as large as albumin.
69. Lawrence B, Dreyfus J, Wen S, et al. CJC-II31, a long acting Glucagon-like peptide-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers [abstract]. Diabetes 2003; 52(suppl 1):A125.
70. Baggio LL, Huang Q, Brown TJ, 2004. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of Glucagon-like peptide-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004; 53: 2492-2500. This study shows that even large-molecular weight analogs of Glucagon-like peptide-1 can activate the neural systems involved in Glucagon-like peptide-1 action on, for example, appetite and the gastrointestinal tract.
71. Bloom M, Bock J, Duttaroy A, et al. Albugon fusion protein: a long acting analogue of Glucagon-like peptide-1 that provides lasting antidiabetic effect in animals [abstract]. Diabetes 2003; 52(suppl 1):A112.
72. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44:1126-1131.
73. Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47:1663-1670.
74. Deacon CF, Hughes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47:764-769.
75. Hansotia T, Baggio L, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory action of DPP-IV inhibitors. Diabetes 2004 (in press).
76. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25:869-875.
77. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:2078-2084. This is the first proof-of-concept study using the DPP-IV inhibitor LAF 237.
78. Ahren B, Gomis R, Standl E, et al. Prolonged efficacy of LAF237 in patients with type 2 diabetes (T2DM) inadequately treated with metformin. Diabetes 2004; 53:7-LB. Although still in abstract form, this important study shows the remarkable clinical effects of a DPP-IV inhibitor in a long-term study.